Clinical Trial

Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer

Study acronym: U-TRANS
Recruiting
View on ClinicalTrials.gov →
Summary
The U-TRANS study was initiated by Gustave Roussy, which is its sponsor\*. It is part of the Interception Program and aims to reduce the consumption of ultra-processed foods in order to improve the overall quality of the diet among people at high risk of cancer (WCRF score ≤ 5, corresponding to low adherence to nutritional cancer prevention recommendations: eating a diet rich in whole grains, vegetables, fruit and fibre, and limiting ultra-processed foods, red meat, processed meats, sugary drinks and alcohol). It assesses the impact of a digital intervention (based on the use of the Open Food Facts app) as a complement to the nutritional education provided by the Interception program.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-09
notable Primary completion pushed: 2027-04 -> 2027-09 2026-05-09
minor Completion pushed: 2027-08 -> 2028-03 2026-05-09
Trial Details
NCT Number NCT07436312
Lead Sponsor Gustave Roussy, Cancer Campus, Grand Paris
Conditions Breast Cancer, Pancreas Cancer, Colon Cancer, Lynch Syndrome, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation
Enrollment 170 participants
Start Date 2026-05-04
Primary Completion 2027-09 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-08